Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 7Ipilimumab 5Nivolumab 4fludarabine 3Radiosurgery 3Drug Therapy 3Cyclophosphamide 3spartalizumab 2aldesleukin 2Sirolimus 2Riluzole 2Radiotherapy 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Oncolytic Virotherapy 2Counseling 2Bupropion 2Blood Specimen Collection 2vofatamab 1utomilumab 1trastuzumab deruxtecan 1toripalimab 1tocilizumab 1sargramostim 1saracatinib 1pertuzumab 1pazopanib 1liposomal doxorubicin 1ixabepilone 1fostamatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × NIS-793 × Thoracic × Clear all
NCT02947165 2022-01-31

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1 Completed
120 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡